Sanara MedTech Inc. announced the closing of its underwritten public offering of 1,265,000 shares of common stock at a public offering price of $25.00 per share, including 165,000 shares of common stock issued pursuant to the full exercise by the underwriters of their option to purchase additional shares of common stock, resulting in gross proceeds of $31.6 million, before deducting underwriting discounts and commissions and estimated offering expenses.
We are pleased to announce the sale of Trilliant Surgical to Colfax.
Sanara MedTech Inc. is acquiring the capability to provide telehealth services for diagnosis and treatments to wound and skin care patients. This entails the development of electronic imagery and data sharing technology that allows clinical information for virtual consultation and diagnosis to be provided remotely to care providers of patients in long-term care and home health settings.
As a way to become an ally with the Black Lives Matter movement, we’ve compiled a list of black owned businesses in both the Houston and Austin area that you can support.
FORT WORTH, TX / ACCESSWIRE / February 10, 2020 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara” or the “Company”) (OTCQB:SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today that on February 7, 2020 The Catalyst Group, Inc. (“Catalyst”) converted into Common Stock Catalyst’s entire holdings of the Company’s 30-month $1,500,000 convertible promissory note and Series F Convertible Preferred Stock.
The Napa Valley resort was named the No. 10 best hotel in the nation in U.S. News' annual list. Auberge du Soleil was recognized for its beautiful scenery, on-site offerings, arranged activities, and gourmet food.
The Family Alignment LLC investment partnership will be managed by The Catalyst Group founder and president Ron Nixon, along with principals Brad Gurasich, David McWhorter and Robert Norris.
A biomedical engineering professor's research on treatment options for optical nerve trauma, particularly for injured soldiers, leads to collaboration with Rochal to develop new material that can deliver doses of therapeutic drugs to injured nerves.